RE:RE:NintedanibTo my point view CZO must move ahead with clinicals trials to evaluate this new approach , it is a must. How many clinicals trials CZO will need to do to get the best deal with a major (1 a, 1b,2a?) , how much will these cliniclas trials will cost? Will CZO decide to conduct those clinicals trials under FDA assesment or only with Health Canada?
Gagnon has a lot of work to do , is he the man that has all the skills to manage this big project? How experienced he is with the FDA , how many big investors can he involved to finance this project? Would it be the time for him to leave his place to someone else? As shareholders are we certain he could maximise shareholders value if PGX-YBG reach a phase 2b for instance?
CZO is defenetly to a turning point and the next main decisions needs to be the right ones.